1. International Agency for Research on Cancer—World Health Organisation. Cancer Today: Data visualization tools for exploring the global cancer burden in 2018 Global Cancer Observatory 2018. http://globocan.iarc.fr/. Accessed 30 June 2021.
2. Kirby M, Hirst C, Crawford E. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–92.
3. Scottish Medicines Consortium—Independent Review Panel. Abiraterone (Zytiga). SMC No. 764/12. 2012. https://www.scottishmedicines.org.uk/media/1185/abiraterone_zytiga_resubmission_final_july_2012_amended_for_website.pdf. Accessed 30 June 2021.
4. Scottish Medicines Consortium- Independent Review Panel. Enzalutamide (Xtandi®). SMC No. 911/13. 2013. https://www.scottishmedicines.org.uk/media/1629/enzalutamide_xtandi_final_october_2013_amended_081113.pdf. Accessed 30 June 2021.
5. Scottish Medicines Consortium- Independent Review Panel. Abiraterone (Zytiga®). SMC No. 873/13. 2015. https://www.scottishmedicines.org.uk/media/1186/abiraterone__zytiga__irp_final_sept_2015_for_website.pdf. Accessed 30 June 2021.